Key cardiology trials in evidence based medicine - click on a trial for more information or a topic above for a summary |
Topic |
Therapy group |
Therapy |
Trial |
Acute coronary syndromes |
ACE inhibitors |
Captopril |
ISIS-4
|
Lisinopril |
GISSI-3
|
Aldosterone antagonists |
Eplerenone |
EPHESUS
|
Anti-platelet therapy |
Aspirin |
ISIS-2,
CURRENT-OASIS-7
|
Clopidogrel |
CURE,
COMMIT,
CURRENT-OASIS-7
|
Prasugrel |
TRITON-TIMI-38,
TRILOGY-ACS,
ACCOAST
|
Ticagrelor |
PLATO
|
Beta-blockers |
Atenolol |
ISIS-1
|
Metoprolol |
COMMIT
|
Diabetic control |
Insulin |
DIGAMI,
DIGAMI-2
|
Ezetimibe |
Added to statin |
IMPROVE-IT
|
Glycoprotein IIbIIIa inhibitors |
In PCI |
CADILLAC,
HORIZONS-AMI
|
Heparinoids |
Fondaparinux |
OASIS-6,
OASIS-5
|
Heparin infusion |
ISIS-3,
OASIS-6
|
Hirudin & Direct Thrombin Inhibitors |
Bivalirudin |
HORIZONS-AMI,
HEAT-PPCI
|
Nitrates |
GTN |
GISSI-3
|
ISMN (MR) |
ISIS-4
|
PCI (STEMI) |
PCI post-thrombolysis |
NORDISTEMI
|
PCI to non-culprit arteries |
PRAMI
|
Thrombus aspiration |
TAPAS
|
PCI (UA/NSTEMI) |
PCI |
TACTICS-TIMI-18,
RITA-3
|
Statins |
Atorvastatin |
PROVE-IT
|
Ezetimibe |
|
Thrombolysis |
Streptokinase |
ISIS-2
|
Streptokinase, rtPA, Alterplase |
ISIS-3
|
Factor Xa inhibitors |
Rivaroxaban |
ATLAS-ACS-2-TIMI-51
|
Atrial Fibrillation |
Ablation |
Paroxysmal AF |
APAF,
ThermoCool-AF
|
RFA (treatment naive) |
MANTRA-PAF
|
Anticoagulation |
Apixiban |
ARISTOTLE
|
Aspirin |
SPAF,
SPAF-II
|
Dabigatran |
RE-LY
|
Rivaroxaban |
ROCKET-AF
|
Warfarin |
SPAF,
SPAF-II,
SPAF-III
|
Rate & Rhythm control |
Dronedarone |
ATHENA,
PALLAS
|
Lenient vs strict rate control |
RACE-II
|
Rate vs. rhythm control |
AFFIRM
|
Coronary heart disease |
ACE inhibitors |
Ramipril |
HOPE
|
ACE inhibitors & ARBs |
Ramipril & Telmisartan |
ONTARGET
|
Angiotensin receptor blockers |
Telmisartan |
ONTARGET
|
Valsartan |
VALUE
|
Lipid therapy |
Niacin |
AIM-HIGH
|
Rosuvastatin |
SATURN
|
Simvastatin |
4S
|
PCI |
2-3 VD (vs. CABG) |
ASCERT
|
LMS/3VD (vs. CABG) |
SYNTAX
|
PCI (vs. medical therapy) |
COURAGE,
FAME-2
|
T2DM - vs OMT/CABG |
BARI-2D,
FREEDOM
|
Heart failure |
ACE inhibitors |
Enalapril |
CONSENSUS,
SOLVD
|
ARBs |
Candesartan |
CHARM
|
Diastolic dysfunction |
CHARM,
I-PRESERVE
|
Valsartan |
ValHeFT
|
Aldosterone antagonists |
Eplerenone (NYHA 2+) |
EMPHASIS-HF
|
Spironolactone (NYHA 3+) |
RALES
|
Anticoagulation |
Warfarin |
WARCEF
|
Beta-blockers |
Bisoprolol |
CIBIS-II
|
Carvedilol |
COMET
|
Devices |
CRT-D |
MADIT-CRT
|
ICD |
SCD-HeFT
|
Glycosides |
Digoxin |
DIG
|
If channel blockers |
Ivabradine |
BEAUTIFUL,
SHIFT
|
Statins |
Rosuvastatin |
CORONA
|
Surgery |
CABG |
STITCH
|
Ultrafiltration |
Cardiorenal syndrome |
CARRESS-HF
|
Hypertension |
ACEi |
Benazepril |
ACCOMPLISH
|
Lisinopril |
ALLHAT
|
Prev. CVA/TIA |
PROGRESS
|
ARB |
Losartan |
LIFE
|
Valsartan |
VALUE
|
Alpha-blockers |
Doxazosin |
ALLHAT
|
CCB |
Amlodipine |
ALLHAT,
VALUE
|
Nitrendipine |
Syst-Eur
|
Diet |
DASH diet |
DASH
|
Renal denervation |
Renal denervation |
Symplicity HTN-2,
Symplicity HTN-3
|
Thiazides |
Chlorthalidone |
SHEP,
ALLHAT
|
Hydrochlorothiazide |
ACCOMPLISH
|
Intervention |
Access |
Radial |
RIVAL
|
Antiplatelet cover |
Dual antiplatelet therapy |
PRODIGY
|
CAD (stable) |
2-/3-VD (vs. CABG) |
ASCERT
|
3VD/LMS disease (vs. CABG) |
SYNTAX
|
MVD in DM vs. CABG |
FREEDOM
|
PCI (vs. medical therapy) |
COURAGE,
FAME-2
|
T2DM - PCI vs OMT/CABG |
BARI-2D
|
Renal denervation |
Resistant hypertension |
Symplicity HTN-2,
Symplicity HTN-3
|
STEMI |
Drug-eluting stents (vs. bare-metal) |
HORIZONS-AMI
|
PCI post-thrombolysis |
NORDISTEMI
|
PCI to non-culprit arteries |
PRAMI
|
Thrombus aspiration |
TAPAS
|
Stents |
Drug-eluting stents (1st generation) |
RAVEL,
TAXUS-IV,
COMPARE
|
Drug-eluting stents (2nd generation) |
COMPARE
|
TAVI |
Non-surgical AS patients |
PARTNER
|
Versus surgery in AS |
PARTNER
|
UA/NSTEMI |
PCI |
TACTICS-TIMI-18,
RITA-3
|
Lipids |
ACS |
Atorvastatin |
PROVE-IT
|
Ezetimibe |
IMPROVE-IT
|
CAD (stable) |
Niacin |
AIM-HIGH
|
Rosuvastatin |
SATURN
|
Simvastatin |
4S
|
Heart failure |
Rosuvastatin |
CORONA
|
Primary prevention |
Ezetimibe |
ENHANCE
|
PCSK9 |
|
Rosuvastatin |
JUPITER
|
Primary prevention (T2DM) |
CARDS |
CARDS
|
Surgery |
CABG |
2-3 VD (vs. PCI) |
ASCERT
|
CCF |
STITCH
|
LMS/3VD (vs. PCI) |
SYNTAX
|
MV disease in DM |
FREEDOM
|
T2DM - vs OMT & PCI |
BARI-2D
|
Test |
Testing therapy |
Testing intervention |
Testing trial
|
Testing intervention2 |
Testing trial
|